Research: Tumorigenesis and resistance to therapy are generally believed to arise through gradual, multigenerational accrual of mutations. However, recent cancer genome sequencing suggests that many cancers may accumulate large number of mutations rapidly, perhaps during the course of a single cell cycle. The most dramatic example of such rapid genome evolution is chromothripsis, a new mutational process with massive chromosome rearrangements and a unique pattern DNA copy number that is curiously restricted to one or a few chromosomes. The mechanism(s) leading to chromothripsis have been unclear, but our group previously suggested that it could result from the physical isolation of chromosomes in abnormal nuclear structures called micronuclei. To test this hypothesis, I developed a procedure to combine live- cell imaging with single-cell whole genome sequencing. This has enabled me, with my collaborators, to recapitulate chromothripsis in the laboratory and demonstrate that it can occur via chromosome fragmentation in micronuclei. This experimental system now positions me to study the mechanism of chromothripsis in detail. I will also test my hypotheses that chromothripsis triggers a downstream cascade of genome instability and drives tumor formation through generation of double minute chromosomes, and that chromothriptic-like DNA damage may be an important facet of the tumor killing action of taxanes. Together, these experiments and the new hypotheses being tested will advance our understanding of the ways by which chromosome segregation errors shape cancer genomes, leading to development of novel therapeutic strategies. Candidate Career Goals: My long-term career objective is to obtain a tenure-track position as a physician-scientist in a radiation oncology department. The K08 award will provide the advanced training necessary to achieve this goal. This research proposal is part of a structured plan with scientific, technical, clinical, and career development components. Environment: DFCI and Harvard University are internationally recognized research programs with a number of expert researchers in the areas of cancer cell biology and genomics. Furthermore, DFCI Department of Radiation Oncology has a distinguished record of training successful physician-scientists. In order to achieve my goals, I will be mentored by two outstanding scientists, Dr. David Pellman and Dr. Matthew Meyerson. I have also assembled an excellent advisory committee, consisting of Dr. Alan D?Andrea, Dr. Tim Mitchison, Dr. Gad Getz and Dr. Harvey Mamon.

Public Health Relevance

Cancers have long been thought to arise by a slow, gradual accumulation of mutations, but recent evidence suggests that some cancers may be caused by a catastrophic event called chromothripsis occurring all at once. I, along with my collaborators, have developed an innovative technique that allowed me to show that chromothripsis can arise from errors in cell division. These findings now position me to uncover the mechanisms by which errors during cell division lead to the accumulation of mutations and chromothripsis in detail, thus allowing us to design more effective drugs that target cancers in the future.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08CA208008-05
Application #
9938444
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Lim, Susan E
Project Start
2016-07-01
Project End
2021-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
5
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Oser, Matthew G; Fonseca, Raquel; Chakraborty, Abhishek A et al. (2018) Cells Lacking the RB1 Tumor Suppressor Gene are Hyperdependent on Aurora B Kinase for Survival. Cancer Discov :
Spektor, Alexander; Umbreit, Neil T; Pellman, David (2017) Cell Biology: When Your Own Chromosomes Act like Foreign DNA. Curr Biol 27:R1228-R1231